19 Reviews
Good work-life balance. Coworkers are generally extremely friendly and willing to help.
Pay is much lower (~1/2) compared to other trading firms. Quickly falling behind competitors in terms of tech and trading. The “3 year goal” has been the same for the past 3 years. Trading side is outdated and traders do not develop any useful career skills. Management decisions and performance are opaque, so nobody has any idea what’s going on or how the firm is doing until company meetings.
IVERIC bio, Inc. (NASDAQ:ISEE - Get Rating) - Investment analysts at Wedbush issued their Q1 2023 earnings estimates for IVERIC bio in a note issued to investors on Monday, October 17th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of ($0.47) per share for the qua
Investment analysts at Barclays increased their price objective for LVMH Mot Hennessy-Louis Vuitton, Société Européenne (OTCMKTS: LVMUY) from €840.00 ($857.14)